Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Codexis, a protein engineering company and developer of novel biotherapeutics, has signed a strategic collaboration and license agreement with Takeda Pharmaceutical Company for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies.

Codexis and Takeda collaborate to advance novel gene therapies
Codexis' CodeEvolver protein engineering technology. Source: Codexis Inc.

Codexis will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using its CodeEvolver protein engineering platform.

Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders.

“The prospects of these improved sequences for the development of differentiated gene therapies for patients with rare disease,s therefore, holds great promise,” stated John Nicols, Codexis’ President and CEO.

The parties will begin collaborative work on three initial programs. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into pre-clinical development. Takeda is responsible for the pre-clinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs.

In addition to the three initial programs, Takeda may initiate up to four additional programs for separate target indications.

Subject to the terms of the agreement, Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and low- to mid-single-digit percentage royalties on sales of any commercial product developed through such initial programs and any other programs that Takeda may elect under the agreement.

Gjalt Huisman, Codexis’ Senior Vice-President, and General Manager, Novel Biotherapeutics said: “We are looking forward to working with Takeda to advance our pre-clinical assets for lysosomal storage disorders, and to broaden our biotherapeutics pipeline to now include blood factor disorders.”

Read More

Related news

New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
European patent granted for amatoxin conjugates for tumor therapy

European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Vaxxas HD-MAP to deliver vaccines directly to the skin

Vaxxas HD-MAP to deliver vaccines directly to the skin

17 Mar 2020

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

Read more 
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

16 Mar 2020

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

Read more 
Technique improves drug delivery system characterization

Technique improves drug delivery system characterization

16 Mar 2020

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

Read more 
Nanoform and Orion collaborate on 'nanoformed' APIs

Nanoform and Orion collaborate on 'nanoformed' APIs

9 Mar 2020

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Read more 
Bristol Myers Squibb disappointed with failed late-stage combo drug trial

Bristol Myers Squibb "disappointed" with failed late-stage combo drug trial

9 Mar 2020

Phase III study evaluating Empliciti plus Revlimid and dexamethasone in patients with newly diagnosed, untreated multiple myeloma fails to meet primary endpoint.

Read more